HBOT Studies Database

The reference document used by Medicare, major payers, and UHMS-accredited facilities to define covered HBOT.

The strongest RCT evidence for HBOT in post-COVID neurological symptoms — 40 sessions at 2.0 ATA, Efrati Lab protocol.

Early UK NHS pilot supporting feasibility — complementary to larger Efrati Lab RCTs.

The theoretical foundation Efrati Lab uses to explain HBOT efficacy across neurological, anti-aging, and tissue-regeneration indications.

First human trial showing HBOT-induced reversal of two hallmarks of aging — cited extensively in longevity media. Mechanism remains debated.

Reference for the oxygen-toxicity calculator — defines pressure/time envelope beyond which seizure risk rises steeply.

Mechanistic evidence that 2.0 ATA HBOT induces measurable angiogenesis in post-concussive brains.

Veteran-population HBOT trial supporting state-level TBI/PTSD programmes (OK, TX, FL).

The ECHM list is the European counterpart to the UHMS 14-indication list. Important for international HBOT practice.

Current Cochrane synthesis supporting UHMS-approved use of HBOT for soft-tissue radionecrosis and osteoradionecrosis.

First prospective HBOT trial in fibromyalgia; suggests disease-modifying rather than merely symptomatic effect.

UHMS approval based on observational evidence — HBOT remains adjunctive to surgical debridement and broad-spectrum antibiotics.

Clinical reference for USN TT6 — definitive emergency treatment for Type I/II DCS and arterial gas embolism.

DoD-funded negative trial. Compare with Harch 2017 — methodological debate over sham-chamber pressure confound continues.

Long-term confirmation that the 2002 Weaver NEJM benefit persists.

Real-world registry study challenging HBOT effectiveness outside strict Wagner 3+ selection — reinforces that patient selection matters.

Early Efrati Lab paper establishing HBOT benefit in chronic post-concussion syndrome using crossover design (patients as own controls).

Supports late-window HBOT (months–years post-stroke) when standard rehabilitation has plateaued.

DoD HOPPS trial — negative primary endpoint but widely criticised for sham chamber delivering ~1.3 ATA O2 (itself potentially therapeutic).

Supports early (<14 day) HBOT referral for idiopathic SSNHL per UHMS 2019 approval.

Current evidence does not support routine HBOT for MS despite widespread use at UK MS Therapy Centres.

Still the most-cited single mechanism reference. Essential reading for understanding HBOT biology.

The strongest RCT supporting UHMS-approved HBOT for Wagner 3+ diabetic foot ulcers. Supports Medicare coverage criteria.

UHMS-approved for early-stage (Steinberg I–II) femoral head AVN as alternative to core decompression.

Controversial — supports mild-HBOT for autism but has been challenged on sham-chamber design and effect size.

UHMS-approved indication based on burn-centre observational experience despite limited RCT data.

Early sports-recovery RCT returning negative result — contrasts with popular athlete marketing of HBOT.

Pivotal RCT establishing 3-session HBOT protocol as standard of care for serious CO poisoning. Weaver protocol remains the referenced treatment schedule.

Important trial often cited as negative, but 1.3 ATA control arm itself may have been active; interpretation remains contested.

Classic RCT supporting UHMS-approved HBOT for Gustilo III crush injuries and compromised limb salvage.

Classic trial establishing the Marx protocol — 20/10 pre- and post-operative HBOT for prevention of osteoradionecrosis after dental extraction in irradiated jaws.

Foundational RCT for UHMS-approved HBOT in compromised skin grafts and flaps.